Literature DB >> 7988813

Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study.

C Niederau1, U Pohlmann, H Lübke, L Thomas.   

Abstract

The present study evaluated the effects of prophylactic administration of cefotaxime in patients undergoing therapeutic or complicated diagnostic ERCP. One hundred patients were randomized to two groups of 50 patients each. Patients in group 1 received an intravenous infusion of 2 g cefotaxime 15 minutes before endoscopy; patients in group 2 did not receive an intravenous antibiotic before ERCP (control group). Blood samples were drawn for bacteriologic cultures before endoscopy and 5, 15, 30, and 120 minutes after beginning the procedure. Bacteremia was detected by blood cultures (15- and 30-minute samples) in 4 patients who did not receive prophylactic antibiotics (Escherichia coli in 2 cases, Peptostreptococcus in 1, and Staphylococcus aureus in 1). Cholangitis or sepsis did not occur after the bacteremic episodes in any of these patients. In 4 other patients who did not receive cefotaxime-all of whom had biliary obstruction-clinical cholangitis or sepsis developed during the 3-day follow-up; ERCP had failed to decompress the biliary system completely in these 4 cases. Blood cultures identified bacteria in 3 of these 4 patients (Pseudomonas aeruginosa in 1, E. coli in 2). Thus, bacteremia or clinical sepsis developed in 8/50 patients (16%) in the control group without antibiotic prophylaxis, whereas no such episode was observed in patients who had received prophylactic treatment (chi 2 = 8.7; p < 0.01). The present results indicate that prophylactic administration of an antibiotic such as cefotaxime can reduce the incidence of bacteremia and sepsis in patients who undergo therapeutic or complicated diagnostic ERCP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988813     DOI: 10.1016/s0016-5107(94)70247-0

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  11 in total

1.  Endoscopic Interventions in the Biliary Tract.

Authors:  Adolf Stiehl
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

2.  Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography.

Authors:  Thawee Ratanachu-ek; Pitchaya Prajanphanit; Kawin Leelawat; Suchart Chantawibul; Sukij Panpimanmas; Somboon Subwongcharoen; Jerasak Wannaprasert
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 3.  Laparoscopic cholecystectomy: consensus conference-based guidelines.

Authors:  Ferdinando Agresta; Fabio Cesare Campanile; Nereo Vettoretto; Gianfranco Silecchia; Carlo Bergamini; Pietro Maida; Pietro Lombari; Piero Narilli; Domenico Marchi; Alessandro Carrara; Maria Grazia Esposito; Stefania Fiume; Giuseppe Miranda; Simona Barlera; Marina Davoli
Journal:  Langenbecks Arch Surg       Date:  2015-04-08       Impact factor: 3.445

4.  Post-ERCP pancreatitis: reduction by routine antibiotics.

Authors:  S Räty; J Sand; M Pulkkinen; M Matikainen; I Nordback
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

5.  Evaluation of Biliary Bacterial Resistance in Patients with Frequent Biliary Instrumentation, One Size Does Not Fit All.

Authors:  Maen Masadeh; Subhash Chandra; Daniel Livorsi; Frederick Johlin; William Silverman
Journal:  Dig Dis Sci       Date:  2018-08-28       Impact factor: 3.199

Review 6.  Preventing nosocomial infections from gastrointestinal endoscopy.

Authors:  D Franchi; A Bahrani; J F Ober; M B Edmond
Journal:  Curr Gastroenterol Rep       Date:  2000-08

Review 7.  Two case reports of gastroendoscopy-associated Acinetobacter baumannii bacteremia.

Authors:  Chang-Hua Chen; Shun-Sheng Wu; Chieh-Chen Huang
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

8.  Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial.

Authors:  O Barkay; E Niv; E Santo; R Bruck; A Hallak; F M Konikoff
Journal:  Surg Endosc       Date:  2008-01-24       Impact factor: 4.584

Review 9.  Biliary tract infections: a guide to drug treatment.

Authors:  J F Westphal; J M Brogard
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

10.  Clinical characteristics and outcomes of spontaneous bacterial peritonitis caused by Enterobacter species versus Escherichia coli: a matched case-control study.

Authors:  Seongman Bae; Taeeun Kim; Min-Chul Kim; Yong Pil Chong; Sung-Han Kim; Heungsup Sung; Young-Suk Lim; Sang-Oh Lee; Mi-Na Kim; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  BMC Infect Dis       Date:  2016-06-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.